NIH to Study Allergic Reactions Linked to COVID-19 Shots
The National Institutes of Health plans to begin a clinical trial that aims to help doctors “predict and manage” allergic reactions related to Pfizer Inc.’s COVID-19 vaccine.
Moncef Slaoui, chief scientific adviser to Operation Warp Speed, said during a Monday news briefing that the aim of the trial, which will also study the Moderna Inc. shot just authorized for emergency use, will be to pinpoint why the incidents, known as anaphylaxis, are occurring.
During the briefing, Slaoui also addressed a new variant of the virus seen in the U.K., saying it’s no more dangerous than other strains and that there is “no hard evidence” it is more transmissible. Getting the data to determine that, he said, will take weeks.
The emergence of the allergic reactions, even in just a handful of cases, and questions surrounding the U.K. mutation have opened new concerns worldwide about the virus. France, Germany, Italy and other countries have already gone as far as blocking travel from the U.K. after the variant was identified.
“It’s clear, it’s not more pathogenic” than other strains of the SARS-CoV-2 virus, Slaoui said. He also said he expects the existing vaccines will likely still offer protection against it.
To date, he said, “there is no hard evidence that this virus is actually more transmissible.” The virus may have been “seeded” more widely in the southeast England area where it’s now being detected with greater frequency.
The NIH study on reactions to the Pfizer vaccine will test the shots “in highly allergic individuals,” Slaoui said. Both the Pfizer and Moderna shots — which are based on similar messenger RNA technology — will be studied, he said.
Both vaccines authorized for emergency use in the U.S. have been ruled generally safe, and both were found to be better than 90% effective in late-stage trials. Side effects noted have included headaches and fatigue, but they have ended within a couple of days.
©2020 Bloomberg L.P.
Distributed by Tribune Content Agency, LLC
In The News
At the onset of the COVID-19 pandemic, it became clear that the nation’s manufacturing capabilities were ill-prepared to respond to the urgent needs of the medical community. As the pandemic’s scope progressed, so did China’s chokehold on supplying countries with personal protective equipment and other front-line... Read More
The Supreme Court on Thursday dismissed a challenge to the Affordable Care Act, preserving insurance coverage for millions of Americans. By a 7-2 vote, the justices left the entire law intact and ruled that Texas and other Republican-led states (as well as two individual plaintiffs) have... Read More
MINNETONKA, Minn. — UnitedHealthcare announced it would delay plans to implement policy changes that would retroactively deny emergency medical care coverage to its customers if the company determines the reason for the care does not qualify as an emergency. Initially set to take effect on July... Read More
Researchers from the Guangzhou Women and Children's Medical Center in China published a study this week in the medical journal Development, offering new insight into preventing infertility in men. Currently, at least 30 million men worldwide are infertile, and one in seven couples are considered clinically... Read More
The House Committee on Financial Services met this past week to discuss how increasing Section 8 housing vouchers could reduce housing instability, overcrowding, and better prepare the nation for the next health or economic crisis. “Providing a voucher to all eligible households would lift 9.3 million... Read More
The COVID-19 pandemic has disrupted routine health services making it difficult to deliver high-quality care to pregnant women and children living with HIV. But it has also pushed global leaders to try and reinvigorate global commitments to eliminate pediatric HIV by 2030. “Children living with HIV... Read More